Table 3 Comparison of LD groups for the Utah breast cancer cases and controls with Applied Biosystems (ABI) data*
Gene | Group | Utah breast cancer case/control SNPs | Utah potential tSNPs | Utah % variance captured/group | ABI SNPs | ABI potential tSNPs | ABI % variance captured/group |
|---|---|---|---|---|---|---|---|
ATM | 1 | A1-A14 | A1-A3, A5, A6, A8-A10, A12-A14 | 98.8% | A1-A14 | A1-A3, A5, A8, A13, A14 | 98.2% |
MRE11 | 1 | M1, M2, M3, M5, M6 | M1, M2, M3, M5, M6 | 100% | M1, M2, M3, M5, M6 | M1, M2, M3, M5, M6 | 100% |
| Â | 2 | M7, M9, M10 | M10 | 84.3% | M7, M9, M10 | M7, M9, M10 | 100% |
| Â | 3 | M11 | M11 | 100% | M11 | M11 | 100% |
| Â | 4 | M4, M8 | M4, M8 | 82.2% | M4, M8 | M4, M8 | 83.9% |
XRCC4 | 1 | X1-X8, X10-X13 | X2-X3, X5-X8, X10-X11 | 95.3% | X1-X8, X10-X13 | X2, X3, X10, X11, X13 | 96.0% |
| Â | 2 | X14, X16-X18 | X14 | 91.6% | X14, X16-X18 | X14, X17, X18 | 93.5% |
| Â | 3 | X19-X21 | X19-X21 | 100% | X19-X21 | X19-X21 | 100% |
| Â | 4 | X9, X15 | X9, X15 | 97.4% | X9, X15 | X9, X15 | 96.8% |